GSK-RTG113413

Study Sponsor: GSK

Study Title

A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults with Partial-Onset Seizures (Extension of Study RGB113905)

Medicine or Vaccine (generic name)

retigabine, ezogabine

Sponsor Identification Number

RTG113413

Trial Registry Identification Number(#'s)

NCT01336621 2010-022777-34

Medical Condition

Epilepsy

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=113413

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT01336621

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2010-022777-34

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This is a follow-up study to RGB113905.

Date Added to this Site

January 2020